Chronic kidney disease should become a priority area of russian healthcare. Statement by the Presidium of the Specialized Commission on Nephrology of the Ministry of Health of the Russian Federation

Read full text
Authors: E. M. Shilov, A. M. Yesayan, N. Yu. Petrova, D. V. Artemov, M. M. Batyushin, A. Yu. Bevzenko, A. N. Belskikh, N. V. Veselkova, S. V. Ivliev, M. E. Statsenko, A. G. Stolyar, M. M. Shilova
Cited by: 2
References: 7

Abstract

Chronic kidney disease (CKD) is the fifth globally socially significant chronic non–communicable disease recognized by WHO. The prevalence of CKD in the world ranges from 10 to 20 % and outstrips the prevalence of diabetes mellitus and cardiovascular diseases (850, 600, and 560 million people, respectively). By 2040, CKD will become the 5th cause of premature mortality, ahead of cancer and diabetes mellitus. In Russia, the prevalence of CKD in risk groups (hypertension, chronic heart failure, and diabetes mellitus) is at least 16 % of the country's population. CKD significantly increases the medical, social, and financial burden on the state budget, a significant part of which is spent on saving the lives of patients who have survived to the end stage renal disease, such as kidney replacement therapy (dialysis, kidney transplantation) and treatment of comorbid conditions. CKD makes a huge contribution to premature mortality. Most patients die from cardiovascular complications (strokes, heart attacks, heart failure) before the development of the terminal stage of the disease. Early detection of the disease will improve the ability to work and enhance the quality of life, as well as increase its duration. Special attention should be paid to risk groups, primarily patients with cardiovascular diseases and diabetes mellitus. The current management strategy for CKD patients is prevention and screening for early manifestations of CKD (decreased glomerular filtration rate and albuminuria), followed by the use of triple cardio–reno-protective therapy (RAAS inhibitors, glyphlozines, synthetic mineralocorticoid receptor blockers), which can slow the progression to the terminal stage of the disease and reduce mortality from cardiovascular complications. Preserving and prolonging the lives of CKD patients requires appropriate government organizational measures – in essence, changing the existing healthcare model focused on the terminal stages of the disease to a model aimed at prevention, early detection, and slowing the progression of CKD

Fields of Study & Subjects

Healthcare Systems and Public Health Chronic Kidney Disease and Diabetes Neurological Disorders and Treatments

Publication details

Journal / source
Nephrology (Saint-Petersburg)
Publisher
Non-profit organization Nephrology
Volume
29
Issue
4
Pages
8–21
Publication date
26 January 2026